Evidence map›Paper›PMID 40864465›Full record

ArticleJAMA network open2025

Low Measles Seropositivity in Vaccinated Children.

Huy Quang Quach, Sara P Jones, Iype Joseph, Alexandria J Powell, Inna G Ovsyannikova, Nathaniel D Warner, Diane E Grill, John B Johnson, Remya Vasanthi Sasi, Archana Mohankumar Ajithakumari and 8 more

Abstract read
In one paragraph

Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Huy Quang QuachMayo Clinic Vaccine Research Group, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Sara P JonesPathogen Biology, BRIC-Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB), Jagathy, Thiruvananthapuram 695014, Kerala, India.
Iype JosephPathogen Biology, BRIC-Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB), Jagathy, Thiruvananthapuram 695014, Kerala, India.
Alexandria J PowellMayo Clinic Vaccine Research Group, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Inna G OvsyannikovaMayo Clinic Vaccine Research Group, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Nathaniel D WarnerDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
Diane E GrillDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
John B JohnsonPathogen Biology, BRIC-Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB), Jagathy, Thiruvananthapuram 695014, Kerala, India.
Remya Vasanthi SasiPathogen Biology, BRIC-Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB), Jagathy, Thiruvananthapuram 695014, Kerala, India.
Archana Mohankumar AjithakumariPathogen Biology, BRIC-Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB), Jagathy, Thiruvananthapuram 695014, Kerala, India.
Raji PrasadPathogen Biology, BRIC-Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB), Jagathy, Thiruvananthapuram 695014, Kerala, India.
Remya ReveendranPathogen Biology, BRIC-Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB), Jagathy, Thiruvananthapuram 695014, Kerala, India.
Jayalekshmi DevakikuttyPathogen Biology, BRIC-Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB), Jagathy, Thiruvananthapuram 695014, Kerala, India.
Vishnu Vikraman MohanakumariPathogen Biology, BRIC-Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB), Jagathy, Thiruvananthapuram 695014, Kerala, India.
Gregory A PolandMayo Clinic Vaccine Research Group, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
M Radhakrishna PillaiPathogen Biology, BRIC-Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB), Jagathy, Thiruvananthapuram 695014, Kerala, India.
Joshy JacobDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia.
Richard B KennedyMayo Clinic Vaccine Research Group, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: India's goal of measles elimination remains unmet, as evidenced by significant recent outbreaks. Objective: To identify seroprevalence rates among vaccinated children and to examine demographic factors that influence antibody responses. Design, Setting, and Participants: This cross-sectional study included a highly vaccinated cohort of Indian children from the states of Kerala and Tamil Nadu between 2018 and 2023. Eligible children had received at least 2 doses of measles-containing vaccines; their mothers were recruited from various community settings, including local nursery and secondary schools, residential associations, and hospitals. Exposure: Measles-specific antibodies were quantified in serum samples. Main Outcomes and Measures: Measles-specific immunoglobulin G (IgG) and neutralizing antibodies were quantified in both children and mothers. Measles-specific IgM was also measured in children. Results: The total cohort comprised 684 children (median age, 9 years [range, 4-18 years]; 348 male [50.1%]) and 544 mothers. All children received at least 2 doses of measles-containing vaccines; 435 children (63.6%) received a third dose, and 7 (1.0%) received a fourth dose. Among the children, 621 (90.8%) had positive measles-specific IgG, and 623 (91.5%) had protective neutralizing antibodies titers, with a strong correlation between measles-specific IgG and neutralizing antibodies (r = 0.73; P < .001). Female children exhibited significantly higher titers of both measles-specific IgG and neutralizing antibodies compared with male children. While IgG and neutralizing antibody titers remained stable over time and were not associated with the number of vaccine doses in children, neutralizing antibody titers increased with age in mothers, likely due to repeated viral exposure. Notably, in 20 families with at least 2 children, differential measles-specific IgM profiles were observed between siblings despite high IgG and neutralizing antibody titers, suggesting ongoing breakthrough infections. Conclusions and Relevance: In this cross-sectional study, substantial measles immunity gaps were found despite high vaccine coverage with evidence of breakthrough infections, posing significant challenges to India's measles elimination efforts. These results underscore the urgent need to strengthen India's immunization program and investigate the mechanisms driving suboptimal responses to measles vaccination; without addressing these immune response deficiencies, achieving measles elimination through increased vaccine coverage alone may remain unattainable in India.

Indexed as

Antibodies, ViralMeaslesMeasles VaccineVaccinationAdolescentAntibodies, NeutralizingChildChild, PreschoolCross-Sectional StudiesFemaleHumansImmunoglobulin GImmunoglobulin MIndiaMaleSeroepidemiologic StudiesAntibodies, NeutralizingAntibodies, ViralImmunoglobulin GImmunoglobulin MMeasles Vaccine

Identifiers

PMID40864465
PMCPMC12391999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.